Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

A key focus of Part III in this clinical trial payment series is the tax implications of trial payments. This article emphasizes that while reimbursements for out-of-pocket expenses are tax-exempt and ...

On this weeks Business of Biotech, Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development company to address an unmet ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and ...

Polymorphs, or different crystalline forms of the same drug, can be selected for distinct properties and patented. A recent court ruling, however, adds new complexity, write experts at Finnegan.

Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discusses overcoming adversity while leading the company through challenging times.

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

Mental health has become one of the significant factors determining early retirement, disability benefits, absenteeism levels, and high societal costs such as productivity losses and medical treatment ...

The article discusses the risks of non-compliance with federal laws in sponsored genetic testing programs and offers insights from Morrison Foerster experts.